VistaPharm recalls 8,901 cases of oxycodone

Pills
Pills

It is not uncommon for companies to have to retrieve products from the market because of packaging problems. A recently acquired Florida maker of generic drugs is now recalling more than 8,900 cases of oxycodone for just such a problem.

According to the most recent FDA Enforcement Report, VistaPharm of Largo, FL, is recalling 8,901 cases of oxycodone hydrochloride oral solution that is shrink-wrapped in 10 unit dose cups after it discovered that excess lidding material had accumulated between the seal and the cup, resulting in leakage.

The voluntary nationwide recall was started last month and this week given a Class II designation by the FDA.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

VistaPharm was acquired late last year by Vertice Pharma for an undisclosed amount. Vertice Pharma announced the deal in November, along with its formation by industry veterans Don DeGolyer and Andrew Saik. The two have a $300 million line of credit from private equity group Warburg Pincus with which they intend to buy both branded and generic products.

DeGolyer most recently served as chief operating officer at Endo Pharmaceuticals. Before that, he was CEO of North America for Sandoz, Novartis' generic pharmaceuticals unit. Saik was most recently chief financial officer at Auxilium Pharmaceuticals, which was acquired last year by Endo.  

- access recall here

Related Article: 
Auxilium dumps QLT inversion deal for $2.6B Endo buyout

Read more on

Suggested Articles

The FDA lambasted Strides Pharma in a warning letter after inspectors found testing records in the trash and in bags by a shredder.

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.

Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.